Study in Cancer Patients With Central Line Associated Clots in the Upper Extremity Treated With Rivaroxaban (Catheter 2)
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
Patients with cancer and an upper extremity DVT associated with a central venous catheter
(CVC) will receive rivaroxaban. CVC survival will be assessed and compared to previous rates
with low molecular weight heparin (LMWH) and warfarin, along with secondary safety outcomes
including bleeding and recurrent venous thromboembolism.
The investigators hypothesize that anticoagulation with rivaroxaban in patients with UEDVT
secondary to central venous catheters in patients with active malignancy is an effective
therapy as quantified by the success of catheter preservation. Prolonged line salvage rate
without recurrence of UEDVT will improve the management of cancer patients who develop an
upper extremity deep venous thrombosis in the setting of a central venous catheter.